Company intelligence / Profile preview

Clock&me

Cambridge, England, United Kingdomluciassociation.org ↗

Ownership: Private
Development stage: Other

Overview

clock.bio has developed a model that can induce aging in human induced pluripotent stem cells (iPSCs), allowing them to study and trigger self-rejuvenation mechanisms. Using genome-wide CRISPR screens, they have identified over 100 genes involved in these processes. The company's approach aims to reverse hallmarks of aging by targeting these genetic pathways, potentially through both novel therapies and drug repurposing. No clinical results are available yet as the company remains preclinical.

Therapeutic areas: OtherNeurology
Modalities: Cell therapyGene therapySmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Clock&me.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clock&me.

Explore the full profile